首页> 美国卫生研究院文献>Oncology Letters >Construction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells
【2h】

Construction and expression of a lentivirus expression vector carrying the VEGF165-EGFP fusion gene in breast cancer MCF-7 cells

机译:携带VEGF165-EGFP融合基因的慢病毒表达载体在乳腺癌MCF-7细胞中的构建及表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vascular endothelial growth factor (VEGF)165 is one of the most abundant and potent angiogenic factors in both physiological and pathological conditions. However, the function and mechanism of VEGF165 in tumors and their environment remain to be elucidated. In the present study, a lentivirus vector (LV) that contained the VEGF165-enhanced green fluorescent protein (EGFP) fusion gene was constructed and transfected into the human breast cancer cell line MCF-7. Following transfection, the expression of VEGF165 in MCF-7 cells was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting. Further cellular localization of VEGF165 was observed through fluorescence microscopy. The titer of the recombinant lentivirus was 5.44×107 TU/ml in the LV-VEGF165-EGFP group and 5.00×108 TU/ml in the LV-EGFP negative control group. RT-qPCR and western blotting demonstrated that the expression of VEGF165 was significantly increased in the LV-VEGF165-EGFP group compared with the control group. The present study lays the foundation for in vitro and in vivo studies on tumor cell derived-VEGF165. Furthermore, the present fusion gene expression vector may provide a potential approach for gene therapy treatment of cancer and other diseases that require regulation of angiogenesis.
机译:血管内皮生长因子(VEGF)165在生理和病理条件下都是最丰富和有效的血管生成因子之一。然而,VEGF165在肿瘤及其环境中的功能和机制仍有待阐明。在本研究中,构建了包含VEGF165增强的绿色荧光蛋白(EGFP)融合基因的慢病毒载体(LV),并将其转染到人乳腺癌细胞系MCF-7中。转染后,通过逆转录-定量聚合酶链反应(RT-qPCR)和western印迹检测MCF-7细胞中VEGF165的表达。通过荧光显微镜观察到VEGF165的进一步细胞定位。重组慢病毒在LV-VEGF165-EGFP组中的滴度为5.44×10 7 TU / ml,在LV-EGFP阴性中为5.00×10 8 TU / ml控制组。 RT-qPCR和western blotting结果表明,与对照组相比,LV-VEGF165-EGFP组VEGF165的表达明显增加。本研究为肿瘤细胞衍生的VEGF165的体外和体内研究奠定了基础。此外,本发明的融合基因表达载体可以提供用于癌症和其他需要调节血管生成的疾病的基因治疗的潜在方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号